Origin(OBK)

RUSTON, LABiotechnology2 H-1B visas (FY2023)

Focus: Origin is a public-stage biotech company founded in 2023 headquartered in Ruston, LA, specializing in nitric oxide-emitting devices and early-stage oncology therapeutics. The company maintains a public listing (ticker: OBK) with a diversified pipeline spanning rare metabolic diseases, oncology, and device-based treatments.

Oncology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Origin

AI assessmentNot Hiring

No open roles listed right now. Follow Origin to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Oricol Test

Non Small Cell Lung Cancer

N/A

Oricol Test

Colorectal Cancer

N/A

Quantification of human DNA retrieved and DNA fragmentation profile.

Help build intelligence for Origin

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong cash position of $470M (FY 2025) provides runway for pipeline advancement without near-term funding pressure
Diversified pipeline across oncology, rare disease (Molybdenum Cofactor Deficiency), and innovative device platforms offers exposure to multiple therapeutic modalities
Public company status with established governance infrastructure provides career stability and potential equity upside

Watch Out For

No active job openings (0 posted roles) suggests minimal hiring momentum or potential organizational restructuring underway
Pipeline shows data quality concerns with several entries appearing to be observational studies, natural history studies, or non-interventional data collection rather than drug candidates
Founded in 2023 with extremely early stage assets (Phase 1/2/3 trials across ultra-rare indications) indicates years to potential commercialization and high clinical risk

Generated by Claude from Origin's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Standard of Care

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT03078933A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers

N/A

A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

Molybdenum Cofactor Deficiency

N/A

Clinical Trials (1)

NCT01735188A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

N/A

Exploratory Study of Rectal Mucus for Diagnosing Disease

Bowel Cancer

N/A

SuperHMO

Healthy Adults

N/A

Clinical Trials (1)

NCT06570330Adult HMO Supplementation and the Gut Microbiome

N/A

SY001

Treatment Related Cancer

N/A

Clinical Trials (1)

NCT06562647SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

N/A

APT001

Foot Ulcer, Diabetic

N/A

Clinical Trials (1)

NCT02356835APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults

N/A

A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum

Molybdenum Cofactor Deficiency

N/A

Clinical Trials (1)

NCT01640717A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)

N/A

Images and cines captured through the capture card

To Validate the Clinical Performance of AI/ML Technologies in First-trimester Pregnant Participants

N/A

Clinical Trials (1)

NCT06952439Clinical Performance Evaluation of the Artificial Intelligence (AI)/ Machine Learning (ML) Technologies Utilized by the Origin Medical EXAM ASSISTANT

N/A

ALXN1101

Molybdenum Cofactor Deficiency (MoCD)

Phase 1

Clinical Trials (1)

NCT01894165Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Phase 1

ORGN001

Molybdenum Cofactor Deficiency, Type A

Phase 2

Clinical Trials (1)

NCT02047461Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

Phase 2

ORGN001

Molybdenum Cofactor Deficiency, Type A

Phase 2/3

Clinical Trials (1)

NCT02629393Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 10 clinical trials

Top TAs: Oncology

H-1B (2023): 2 approvals

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Net Income

$84M

Cash

$470M

Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo